At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/innovative-medicine Johnson & Johnson Innovative Medicine is recruiting for Senior Director, R&D Data Science & Digital Health – Neuropsychiatry. This position can be located in one of our office locations in either Cambridge, MA (preferred), Spring House, PA, Titusville, NJ, or San Diego, CA. May require approximately 25 % domestic and international travel. At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ . Role Summary We are seeking an experienced and visionary Senior Director to lead our data science and digital health strategy for neuropsychiatry . This role will shape and execute innovative approaches leveraging multiomics, digital health technologies, artificial intelligence, and clinical/real-world evidence (RWE) to accelerate drug discovery, development, and patient impact. You will partner closely with Neuroscience Therapeutic Area, Clinical Development, Quantitative Sciences, Regulatory and Patient Reported Outcomes as well as external collaborators to drive a precision neuroscience agenda. This position offers the opportunity to transform how we understand disease biology, identify novel endpoints, stratify patients, and deliver better outcomes for people living with neuropsychiatric disorders.